Hepatitis E Virus: What Transplant Physicians Should Know

Authors

  • N. Kamar,

    Corresponding author
    1. Department of Nephrology, Dialysis and Organ Transplantation, CHU Rangueil, Toulouse, France
    2. INSERM U1043, IFR–BMT, CHU Purpan, Toulouse, France
    3. Université Paul Sabatier, Toulouse, France
    Search for more papers by this author
  • F. Legrand-Abravanel,

    1. INSERM U1043, IFR–BMT, CHU Purpan, Toulouse, France
    2. Université Paul Sabatier, Toulouse, France
    3. Department of Virology, CHU Purpan, Toulouse, France
    Search for more papers by this author
  • J. Izopet,

    1. INSERM U1043, IFR–BMT, CHU Purpan, Toulouse, France
    2. Université Paul Sabatier, Toulouse, France
    3. Department of Virology, CHU Purpan, Toulouse, France
    Search for more papers by this author
  • L. Rostaing

    1. Department of Nephrology, Dialysis and Organ Transplantation, CHU Rangueil, Toulouse, France
    2. INSERM U1043, IFR–BMT, CHU Purpan, Toulouse, France
    3. Université Paul Sabatier, Toulouse, France
    Search for more papers by this author

Nassim Kamar, kamar.n@chu-toulouse.fr

Abstract

Hepatitis E virus (HEV) infection is an underdiagnosed disease in the developed world. In pediatric and adult organ transplant patients HEV infection can cause chronic hepatitis, which can lead to cirrhosis. Extra-hepatic manifestations, such as neurological symptoms and kidney injury, have been also reported in transplant patients. In this comprehensive minireview, we summarize the current knowledge on HEV infection in transplant patients, that is, its prevalence, incidence, natural history and therapy.

Ancillary